NEFA

NEFA
Name	NEFA
Othernames	Non-esterified fatty acid; Free fatty acid
Formula	variable (R–COOH)

NEFA Non-esterified fatty acids (NEFA), commonly called free fatty acids, are carboxylic acids with long hydrocarbon chains released from triglycerides and phospholipids. They circulate bound to albumin in plasma and serve as key substrates for mitochondrial beta-oxidation, membrane synthesis, and signaling. NEFA concentrations vary with nutritional state, hormonal milieu, and pathological conditions such as insulin resistance, sepsis, and ischemia.

Definition and Nomenclature

The term NEFA denotes molecules formally named as fatty acids (e.g., palmitic acid, oleic acid, linoleic acid) that are not esterified to glycerol or other backbones. Historically, terminology has alternated among "free fatty acids" (FFA), "nonesterified fatty acids" (NEFA), and "unbound fatty acids" in literature from influential groups such as the American Heart Association and journals like Nature Medicine. Systematic nomenclature follows IUPAC rules where each fatty acid is designated by carbon chain length and unsaturation (for example, 18:1 cis-9, also known by trivial name Oleic acid). Clinical chemistry panels and metabolic studies often adopt "NEFA" to avoid ambiguity with intracellular esterified pools measured in studies by investigators affiliated with institutions such as Harvard Medical School or Imperial College London.

Biochemistry and Physiology

NEFA arise from the enzymatic hydrolysis of triglycerides by lipases including Hormone-sensitive lipase and Adipose triglyceride lipase in adipocytes, and by pancreatic lipase in the digestive tract. After release, NEFA are transported predominantly bound to albumin synthesized by the Liver and are taken up by tissues such as skeletal muscle, cardiac myocytes, and the Brain under certain conditions. In mitochondria, enzymes of the beta-oxidation pathway (e.g., Acyl-CoA dehydrogenase) convert NEFA into acetyl-CoA, feeding the Tricarboxylic acid cycle and oxidative phosphorylation complexes originally characterized in studies from laboratories at Max Planck Society. NEFA also participate in signaling via nuclear receptors including Peroxisome proliferator-activated receptor alpha and G-protein-coupled receptors such as GPR40 (FFAR1), linking metabolic status to transcriptional programs and hormone secretion studied by teams at institutions like Massachusetts Institute of Technology.

Measurement and Laboratory Methods

Quantification of NEFA in plasma employs colorimetric assays, enzymatic kits, and mass spectrometry platforms established by analytical groups at Stanford University and industry leaders. Early methods used the copper soap or acyl-CoA synthetase–acyl-CoA oxidase coupled reactions standardized in protocols from laboratories associated with World Health Organization reference centers. Contemporary approaches favor liquid chromatography–tandem mass spectrometry (LC-MS/MS) with stable isotope-labeled internal standards developed in consortia including Centers for Disease Control and Prevention metabolomics initiatives. Preanalytical factors such as fasting state, tourniquet application, and sample storage at biobanks like those at University of Oxford affect NEFA values, prompting guidelines from professional bodies including the College of American Pathologists.

Clinical Significance and Pathophysiology

Elevated NEFA concentrations are implicated in the pathogenesis of insulin resistance, type 2 diabetes mellitus, and cardiovascular disease; foundational clinical observations were reported in cohorts by investigators at Framingham Heart Study and trials led by National Institutes of Health. NEFA-mediated lipotoxicity involves ectopic lipid accumulation in organs such as the Pancreas and Skeletal muscle and activation of inflammatory pathways involving toll-like receptors originally characterized in research from Rockefeller University. During acute stress, sepsis, or myocardial infarction (documented in registries like American College of Cardiology datasets), NEFA levels rise due to catecholamine-driven lipolysis, contributing to arrhythmogenesis and myocyte dysfunction described in studies from Cleveland Clinic. In obstetrics, altered NEFA dynamics have been associated with gestational diabetes and fetal growth patterns examined in cohorts at Johns Hopkins University.

Regulation and Metabolism

Hormonal regulators of NEFA include insulin, catecholamines (through Adrenergic receptors), glucagon, and natriuretic peptides; seminal endocrine experiments were conducted at institutions like Columbia University. Insulin suppresses adipocyte lipolysis via signaling cascades involving Protein kinase B and Phosphodiesterase 3B, reducing circulating NEFA. Perilipin and comparative gene identification-58 (CGI-58) modulate access of lipases to lipid droplets, with genetic variants studied at centers such as European Molecular Biology Laboratory. Hepatic re-esterification pathways convert NEFA into triglycerides for very-low-density lipoprotein assembly, processes elucidated in research from Wellcome Trust–funded laboratories. Mitochondrial uptake of long-chain NEFA requires activation by acyl-CoA synthetases and translocation via the carnitine shuttle components like Carnitine palmitoyltransferase I.

Research and Therapeutic Implications

Active research explores targeting NEFA flux to treat metabolic disease, with trials testing agents such as Thiazolidinediones that modulate adipose storage and drugs affecting lipolysis or mitochondrial fatty acid oxidation evaluated in multi-center trials coordinated by groups like European Society of Cardiology. Metabolomics consortia including projects at Broad Institute integrate NEFA profiling with genomics to identify biomarkers predictive of outcomes in cohorts from UK Biobank. Therapeutic strategies consider manipulating receptors such as GPR120 and nuclear factors like PPAR gamma to alter NEFA signaling, while interventions including bariatric surgery cohorts at Mayo Clinic demonstrate durable reductions in circulating NEFA. Ongoing translational work spans collaborations among pharmaceutical companies, academic centers including University of California, San Francisco, and regulatory agencies such as Food and Drug Administration to validate NEFA as both biomarker and therapeutic target.

Category:Metabolism